Clinical Trials | December 18, 2025
Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer
The combination also outperformed chemotherapy on another important secondary endpoint
The combination also outperformed chemotherapy on another important secondary endpoint
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
Annual EBITDA margin expands by 170 basis points
Subscribe To Our Newsletter & Stay Updated
